Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Non Operating Income (2018 - 2025)

Corcept Therapeutics' Non Operating Income history spans 8 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 19.04% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $21.7 million, down 11.72%, while the annual FY2025 figure was $21.7 million, 11.72% down from the prior year.
  • Non Operating Income for Q4 2025 was $5.4 million at Corcept Therapeutics, up from $5.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.7 million in Q4 2024 and bottomed at $72000.0 in Q3 2021.
  • The 5-year median for Non Operating Income is $4.3 million (2023), against an average of $3.4 million.
  • The largest annual shift saw Non Operating Income tumbled 89.11% in 2021 before it soared 4376.25% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $72000.0 in 2021, then soared by 2368.06% to $1.8 million in 2022, then surged by 189.2% to $5.1 million in 2023, then soared by 30.34% to $6.7 million in 2024, then dropped by 19.04% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Non Operating Income are $5.4 million (Q4 2025), $5.0 million (Q3 2025), and $5.0 million (Q2 2025).